
    
      This will be a single-center, single-dose study. The study will be a randomized,
      double-blind, placebo-controlled, single-dose study. Patients who are undergoing cadaveric
      orthotopic liver transplantation and are at risk for development of DGF, based upon known
      risk factors, will be eligible to participate in the study. 12 patients will be enrolled in
      the study.
    
  